Target intelligence / Profile preview

Alpha-like protein 1 (Alp1) (Alp1)

Target
Alp1
Molecular classification
Bacterial surface protein, Adhesin, Antigen
01

Overview

Alpha-like protein 1 (Alp1), also known as Epsilon, is a critical surface-anchored protein found in Streptococcus agalactiae (Group B Streptococcus or GBS), which is a leading cause of life-threatening neonatal infections (UniProt P0C0U1). It belongs to the Alpha-like protein (Alp) family, a group of virulence factors characterized by a conserved N-terminal domain and a variable number of tandem repeats that facilitate bacterial adhesion to host epithelial cells (PubMed 22434305). Alp1 plays a significant role in immune evasion by interfering with the host complement system, thereby enhancing bacterial survival within the bloodstream (PubMed 15103025). Due to its high prevalence in clinical isolates and its ability to elicit protective opsonophagocytic antibodies, Alp1 is a primary target for the development of maternal vaccines intended to provide passive immunity to newborns (PubMed 33166118). Current therapeutic strategies, such as the hexavalent GBS6 vaccine, utilize the N-terminal domains of Alp1 and other family members to provide broad-spectrum protection against diverse GBS serotypes (ClinicalTrials.gov NCT03765073).

Other names
Epsilon proteinAlp1Surface protein Alp1Alpha-like protein EpsilonGroup B Streptococcus Alpha-like protein 1
02

Mechanism of action

Induction of opsonophagocytic antibodies (IgG) that recognize the N-terminal domain of the protein, facilitating bacterial clearance by host immune cells.

03

Biological functions

Cell adhesionImmune evasionBacterial virulenceHost cell interaction
04

Disease associations

Group B Streptococcal infectionNeonatal sepsisMeningitisPneumonia
05

Safety considerations

Immunogenicity variability across different populationsPotential for bacterial strain escape through antigenic variationRequirement for multi-component formulation to ensure broad coverage
06

Interacting drugs

GBS6 vaccine (Hexavalent GBS polysaccharide-protein conjugate vaccine)

1 more in the full profile.

07

Biomarkers

Anti-Alp1 IgG antibody titersOpsonophagocytic killing assay (OPKA) titers

Beyond the preview

Go deeper on Alpha-like protein 1 (Alp1) (Alp1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-like protein 1 (Alp1) (Alp1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call